Salman A, et al. - In this retrospective cohort study involving 42 patients, researchers examined the influence of omalizumab on quality of life (QoL) and its predictors in chronic spontaneous urticaria (CSU). The response to therapy was assessed utilizing urticaria activity score over 7 days (UAS7) and urticaria control test (UCT) and the impairment in QoL was evaluated utilizing dermatology life quality index (DLQI) and chronic urticaria quality of life questionnaire (CU-Q2oL). Investigators found that all scores improved from baseline to the first month and remained stable during the third month of therapy. Gender, age, and angioedema did not have any significant impact on QoL, but the complete responders (UAS7:0–1) had a better rate of improvement in all scores vs others. The baseline scores for UAS7, DLQI, and CU-Q2oL were smaller in complete responders at the baseline. The data presented in this work showed a fast and continual improvement in QoL with omalizumab treatment. A better baseline UAS7, UCT, DLQI, and CU-Q2oL score could be a predictor of a better omalizumab response and a greater QoL improvement.